• Return to search results
• Start new search

Investigator(s):
Wyndham H. Wilson, M.D., Ph.D. Principal Investigator Phone: 301-435-2415 wilsonw@mail.nih.gov	Alan Wayne, M.D. Protocol Chair Phone: 301-496-4256 waynea@mail.nih.gov
Referral Contact(s):
Nicole Grant, R.N. Research Nurse Phone: 301-594-2947 grantn@mail.nih.gov	Peggy Shovlin, R.N., B.S.N. Research Nurse Phone: 301-594-6597 mshovlin@mail.nih.gov

---

Primary Eligibility:

• Aggressive HIV+, CD20+, non-Hodgkin's lymphoma
• All stages of disease
• No primary CNS lymphoma
• No previous chemotherapy or rituximab
• Not pregnant or nursing
• Age 4 years and older
• No current clinical heart failure or symptomatic ischemic heart disease

---

Treatment Plan:

• Patients receive EPOCH for 3 courses, up to a maximum of 6 cycles or 1 cycle beyond complete remission or stable disease
• Patients receive rituximab on day 1 and 5 of every cycle
• Patients also receive CNS prophylaxis, methotrexate, on days 1 and 5 of courses 3-5
• Sites of active disease are re-imaged every cycle starting after cycle 2

---

Additional Information:

• This trial will be conducted at the NIH Clinical Center in Bethesda, MD. It is open to patients who meet the eligibility requirements, regardless of where they live in the United States.
• There is no charge for medical care received at NIH Clinical Center.
• FAQs about this study - provides information for patients about the trial such as frequency and duration of visits, costs, how to enroll, treatment plan.
• PDQ (Physicians Data Query) - provides additional details about this study for health care providers.

Reviewed: 10/28/08
Updated: 9/1/06